Express Mail Label No. EV 292461050US Date of Deposit: March 17, 2004 Docket No. M0656.70070US00

FORM PT	O-1449/A and B (1	Aodifie	d)	APPLICATION NO	.: 09/982,548	ATTY. DOCKET NO.: M0656.70070US00			
	DRMATION 1			FILING DATE:	October 18, 2001	CONFIRMATION NO.: 7782			
STA	TEMENT BY	API	PLICANT	APPLICANT:	APPLICANT: Liu et al.				
Sheet	1	of	4	GROUP ART UNIT	: 1623	EXAMINER: McIntosh III, Traviss C			

U.S. PATENT DOCUMENTS

			0.3.	PATENT DOCUMENTS	
xaminer's	Cite	U.S. Patent Do	cument	Name of Patentee or Applicant of Cited	Date of Publication or of issue
nitials	No.	Number	Kind Code	Document	of Cited Document MM-DD-YY
(H)	A53	4,551,296		Kavesh et al.	11-05-1985
	A54	4,830,013		Maxwell	05-16-1989
	A55	4,928,694		Maxwell	05-29-1990 MAR 1 7 ZDG
	A56	5,453,171		Ma et al.	05-29-1990 MAR 1 / ZIM
	A57	5,569,366		Chen et al.	10-29-1996 BADEMARKS
	A58	5,607,859		Biemann et al.	03-04-1997
•	A59	5,687,090		Chen et al.	11-11-1997
	A60	5,752,019		Rigoutsos et al.	05-12-1998
	A61	5,759,767		Lakowicz et al.	06-02-1998
	A62	5,767,269		Hirsh et al.	06-16-1998
	A63	5,952,653		Covey et al.	09-14-1999
	A64	5,990,097		Kennedy	11-23-1999
	A65	5,993,846		Friedman et al.	11-30-1999
	A66	6,190,875	B1	Ben-Artzi et al.	02-20-2001
	A67	6,268,146	B1	Shultz et al.	07-31-2001
	A68	6,291,439	BI	Klock	09-18-2001
-00	A69	6,309,853	B1	Friedman et al.	10-30-2001
11/	A70	6,333,051	B1 '	Kabanov et al.	12-25-2001
1	A71	6,597,996	BI	Venkataraman et al.	07-22-2003

FOREIGN PATENT DOCUMENTS

xaminer's	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
nitials	No.	Office/ Country	Number	Kind Code	(not necessary)	Cited Document MM-DD-YYYY	(Y/N)
(12)	B15	EP	0 114 589	B1	President and Fellows of Harvard College	09-23-1987	
$\mathcal{D}$	B16	ЕР	0 140 781		DROPIC Societe Civile de Gestion de Droit de Propriete Industrielle CHOAY	05-08-1985	Y- ABSTRACT ONLY
12	B17	EP ·	0 244 236	A2	Novo Industri A/S	11-04-1987	
(P)	B18	EP	0 342 215	Bl	Genentech, Inc. et al.	08-25-1993	
	B19	EP	0 394 971	A1	KabiVitrum AB et al.	10-31-1990	
(D)	B20	wo	92/01003	Al	Board of Regents, the University of Texas System	01-23-1992	
19	B21	WO	93/05167	A1	Children's Medical Center Corporation	03-18-1993	
19	B22	wo	93/10450 A1 Glyko, Inc.		Glyko, Inc.	05-27-1993	
(V)	B23	wo	93/15406	A1	Imperial College of Science, Technology and Medecine	08-05-1993	
$\mathcal{L}^{2}$	B24	WO	94/12618	Al	Massachusetts Institute of Technology et al.	06-09-1994	

275.1

APPLICATION NO.: 09/982,548 RM PTO-1449/A and B (Modified) ATTY. DOCKET NO.: M0656.70070US00 INFORMATION DISCLOSURE FILING DATE: CONFIRMATION NO.: 7782 October 18, 2001 STATEMENT BY APPLICANT APPLICANT: Liu et al. GROUP ART UNIT: 1623 EXAMINER: McIntosh III, Traviss C 2 of

(in)	B25	WO	95/13830	A1.	Massachusetts Institute of Technology et al.	05-26-1995	
(Y)	B26	wo	96/01648	Al	Ibex Technologies R and D, Inc.	01-25-1996	
0	B27	WO	97/11684	Al	Ibex Technologies, Inc.	04-03-1997	
B	B28	WO	98/04902	Al	The State of Oregon	02-05-1998	

	DLI	110	71111004	71.	tock recitionegies, inc.	U <del>4-</del> UJ-1771		
B	B28	WO	98/04902	Al	The State of Oregon	02-05-1998		
			OTHE	RART — No	ON PATENT LITERATURE DOC	UMENTS		
aminer's	Cite				ITAL LETTERS) title of the article (		Transla	
ials	No	(book, n	nagazine, journ		mposium, catalog, etc.), date, relevant		(Y/	N)
	047	ALCED -			sher, city and/or country where publis		<b></b>	r
	C47	AMEER E	al., "A New A	pproach to N	tegional Heparinization: Design and L	Development of a Novel Immobilized		
					n Meeting Information: The Internati	onal Conjerence on Continuous		
Control of	C49				07-108, 1998. ABSTRACT ONLY	60 1		<b>├</b> ──
12 31	C48				Al Structure of the Alkaline Protease of			
A CO					g Parallel Beta Roll Motif', The EMB	, , , ,		
W.	C49				nte Glycosaminoglycans are Responsi			
123					Different Fibroblast Growth Factor R	eceptors", The FASEB Journal,		
- 3		Express Ar	ticle No.: 10.10	96/fj.00-066	lfje: 1-19, 2001.			
E (	C50				re Determination by Mass Spectromet	ry: From Alkaloids to Heparin", J.		
W)		Am. Soc. M	lass. Spectrom.	, 13: 1254-12	272, 2002.			<u> </u>
	C51				rombin III Isoforms on Immobilized I			
(40)				s of Low-aff	inity Heparin Sites", The Journal of I	Biological Chemistry, 263(5):2187-		
		2194, 1988						
(1)	C52			nation Enhar	ncement Methods for Large Scale Seq	uence Analysis", Computers Chem.,		
4		17(2): 191-					L	<b> </b>
0	C53				ate Lyase C: Something to Sneeze At			
92	C54		•		ls Inhibits Angiogenesis in the Presen	ce of Heparin or a Heparin		
7			Science, 230:					
(c)	C55				an Sulfates Mediate Cationic Peptide			1
0					Physiol. Lung Cell Mol. Physiol., 285			
$\langle \mathcal{A} \rangle$	C56				hia coli, Purification and Characteriza	ation of Heparinase I from		
		Flavobacte	rium heparinui	n', Biochem	. J., 315: 589-597, 1996.			
	C57				n of Glycosaminoglycans", Critical R	eviews in Biochemistry and		
	060	Molecular .	Biology, 30(5):	38/-444, 19	bition and Tumor Regression Caused	1 11 ' II		
	C58					by Heparin or a Heparin Fragment		1
	C59	ED ANIVI D	Not al "Brass	le , Science,	. 221:719-725, 1983. uginosa AlgG is a Polymer Level Alg	insta CS Managemen Enimense?		
10	C39		N et al., Frend Bacteriology, I			mate C3-iviannuronan epimerase,		١.
	C60				nes: A Proposed Unified Mechanism	of Astion for the Largest and		<del> </del>
(4)	C00		ngmauc-mous", <i>FEBS Letter</i>			of Action for the Lyases and		
	C61				Phosphorylated and Sulfated Linkage	region Oligosassharides in		<del> </del>
	COI				Sulfate Proteoglycans by High Perform			
1(15)					1997-2007, 1999.	nance Elquid Chromatography , 3.		
$\sim$	C62				om Flavobacterium heparinum: Role o	of Positive Charge in Enzymatic	<del>                                     </del>	<del> </del>
$(\mathcal{D})$	~~				hemistry, 273(1): 248-255, 1998.	or i oshive charge in Linzymane		13
	C63	GUERRIN	Let al "A Nov	el Computat	tional Approach to Integrate NMR Sp	ectroscopy and Capillary	<del></del>	<del></del>
					ent of Heparin and Heparan Sulfate O			
			3-719, 2002.	·	···· ·································	g		
	C64	HAYES. "I	Prototeins". Am	erican Scien	tist, the Magazine of Sigma Xi, the Sc	cientific Research Society. 86(3):	<u> </u>	
100		216-221, 1			,			
	C65			PCR". PCR	Protocols: A Guide to Methods and	Applications, Academic Press. Inc	T	
(P)			Chapter 22, 17		The second secon	Alternational comments a committee of the committee of th		
	C66				t Skin Heparin Chains with High Affi	nity for Antithrombin". Biochem. J		
11/1		244: 693-69	98, 1987.		•			l

APPLICATION NO.: 09/982,548 ATTY. DOCKET NO.: M0656.70070US00

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 3 of 4

APPLICATION NO.: 09/982,548 ATTY. DOCKET NO.: M0656.70070US00

FILING DATE: October 18, 2001 CONFIRMATION NO.: 7782

APPLICANT: Liu et al.

GROUP ART UNIT: 1623

EXAMINER: McIntosh III, Traviss C

	-			
112	C67	JOHNSON et al., "Endothelial Cells Preparing to Die by Apoptosis Initiate a Program of Transcriptome and		
6	CCO	Glycome Regulation", The FASEB Journal, 18: 188-190, 2004.	-+	
	C68	KEISER et al., "Direct Isolation and Sequencing of Specific Protein-binding Glycosaminoglycans", Nature Medicine, 7(1): 123-128, 2001.		
1	<b>4</b> 069	KISHIBE et al., "Structural Requirements of Heparan Sulfate for the Binding to the Tumor-derived Adhesion		
- 6 than 1	B	Factor/ Angiomodulin that Induces Cord-like Structures to ECV-304 Human Carcinoma Cells", The Journal of		
Kar-	EFICE S	Biological Chemistry, 275(20): 15321-15329, 2000.		
	9C70	LECKBAND et al., "Characterization of the Active Site of Heparinase", Abstracts of Papers Part 1: Fourth		
TRADE TO	/	Chemical Congress of North America, 202(1): a56, 1991.		
LEADF YOU	C71	LEWIN, Genes V, p.13, 1994.	$-\!\!\!\!-\!$	
13	C72	LIU, Dongfang, et al., "Dynamic Regulation of Tumor Growth and Metastasis by Heparan Sulfate Glycosaminoglycans", Seminars in Thrombosis and Hemostasis, 28(1): 67-78, 2002.		
(1)	C73	LIU, Dongfang, et al., "Tumor Cell Surface Heparan Sulfate as Cryptic Promoters or Inhibitors of Tumor		
	0,0	Growth and Metastasis", PNAS, 99(2): 568-573, 2002.		
13	C74	LIU, Jian, et al., "Strategy for the Sequence Analysis of Heparin", Glycobiology, 5(8): 765-774, 1995.		
السين	C75	LIU, Jian, et al., "Characterization of a Heparan Sulfate Octasaccharide that Binds to Herpes Simplex Virus		.
(a)		Type 1 Glycoprotein D", The Journal of Biological Chemistry, 277(36): 33456-33467, 2002.		
	C76	MARCINIAK, "Differential Role of Fractionated Heparin in Antithrombin-III Proteolysis", Blood, 59(3): 576-		
1/4		581, 1982.		ļ
<u> </u>	C77	McLEAN et al., "Enzymic Removal of 2-O-Sulphato-A <sub>4.5</sub> -Glycuronic Acid Residues from Heparin		
19	•	Oligosaccharides", Proc. of the 7th Int'l. Symposium of Glycoconjugates, p.68-69, 1983.		1
-	C78	MURPHY et al., "Basic Fibroblast Growth Factor Binding and Processing by Human Glioma Cells", Molecular		$\neg$
(00)	0.0	and Cellular Endocrinology, 114: 193-203, 1995.		ı
	C79	MYETTE et al., "The Heparin / Heparan Sulfate 2-O-Sulfatase from Flavobacterium heparinum", The Journal		
10	0.7	of Biological Chemistry, 278(14): 12157-12166, 2003.	1	ļ
	C80	MYETTE et al., "Molecular Cloning of the Heparin / Heparan Sulfate Δ4,5 Unsaturated Glycuronidase from		
(D)	000	Flavobacterium heparinum, its Recombinant Expression in Escherichia coli, and Biochemical Determination of	l	- 1
4		its Unique Substrate Specificity", Biochemistry, 41(23): 7424-7434, 2002.	L	
,	C81	MYETTE et al., "Expression in Escherichia coll, Purification and Kinetic Characterization of Human Heparan		
to		Sulfate 3-O-Sulfotransferase-1", Biochemical and Biophysical Research Communications, 290(4): 1206-1213,		- 1
		2002.		
,	C82	NATKE et al., "Heparinase Treatment of Bovine Smooth Muscle Cells Inhibits Fibroblast Growth Factor-2		- 1
1		Binding to Fibroblast Growth Factor Receptor but not FGF-2 Mediated Cellular Proliferation", Angiogenesis, 3:		
(V)		249-257, 1999.		
	C83	NESHEIM et al., "Dependence of Antithrombin III and Thrombin Binding Stoichiometries and Catalytic	1	l
(1/2)		Activity on the Molecular Weight of Affinity-purified Heparin", The Journal of Biological Chemistry, 261(7):		ı
		3214-3221, 1986.	$\longrightarrow$	—
FD	C84	PADERA et al., "FGF-2/ Fibroblast Growth Factor Receptor/ Heparin-like Glycosaminoglycan Interactions: A	1	
<u> </u>	L	Compensation Model for FGF-2 Signaling", The FASEB Journal, 13(13): 1677-1687, 1999.		
(m)	C85	PIXLEY et al., "Preparation of Highly Stable Antithrombin-sepharose and Utilization for the Fractionation of	- 1	1
112		Heparin", Thrombosis Research, 26(2): 129-133, 1982.		
(ou)	C86	POJASEK et al., "Biochemical Characterization of the Chondroitinase B Active Site", The Journal of Biological	-	I
10/		Chemistry, 277(34): 31179-31186, 2002.		
1	C87	POJASEK et al., "Recombinant Expression, Purification, and Kinetic Characterization of Chondroitinase AC		I
(2)		and Chondroitinase B from Flavobacterium heparinum", Biochemical and Biophysical Research	[	
		Communications, 286(2): 343-351, 2001.	<del></del>	
	C88	RAMAN et al., "Identification of Structural Motifs and Amino Acids within the Structure of Human Heparan	-	
0		Sulfate 3-O-Sulfotransferase that Mediate Enzymatic Function", Biochemical and Biophysical Research	- 1	
	COD	Communications, 290(4): 1214-1219, 2002.   RAMAN et al., "The Heparin / Heparan Sulfate 2-O-Sulfatase from Flavobacterium heparinum: A Structural		
(2)	C89	RAMAN et al., "The Heparin / Heparan Sultate 2-O-Sultatase from Playobacterium neparinum: A Structural and Biochemical Study of the Enzyme Active Site and Saccharide Substrate Specificity", The Journal of	1	1
104			- 1	
		Biological Chemistry, 278(14): 12167-12174, 2003.	-	-
	L			

	• *	MAR 1 7 2004				
M PTO	-1449/A a	nd B (Modified)	APPLICATION NO.: 09/98	2,548	ATTY. DOCKET NO.: M0656.70	007 <b>0</b> US00
FOF	RMATI	ON DISCLOSURE"	FILING DATE: Octob	per 18, 2001	CONFIRMATION NO.: 7782	
AT.	EMEN'	Γ BY APPLICANT	APPLICANT: Liu et	al.		
	4	of 4	GROUP ART UNIT: 1623		EXAMINER: McIntosh III, Trav	viss C
9	C90	with Heparinases", 45th Annual ABSTRACT ONLY	Conference of Mass Spectrome	etry Allied Topi		
D	C91		ectrometric and Capillary Electr (Department of Chemistry), 19		stigation of Heparin, Heparinases,	r¥)
125	C92		Sequencing Technology", Nati			
5	C93	SASISEKHARAN et al., "Role 528, 2002.	es of Heparan-sulphate Glycosa	minoglycans in	Cancer", Nature Reviews, 2: 521-	
(A)	C94		iews of Heparan Sulfate Glycos al Functions", TCM, 12(2): 71-7		tructure / Activity Relationships	
D	C95	SUNDARAM et al., "Rational PNAS, 100(2): 651-656, 2003.	Design of Low-molecular Weig	ght Heparins wi	ith Improved In vivo Activity",	
W	C96	TAYLOR et al., "Protamine is	an Inhibitor of Angiogenesis",	Nature, 297: 30	7-312, 1982.	
(e)	C97		utation Converts a Novel Phosp Journal of Biological Chemistry			
<u></u>	C98		ion of a β-Ketoacyl Synthase to amine", Biochemistry, 38(36): 1		carboxylase by Replacement of the 999.	
i)	C99	YAMADA et al., "Structural S	tudies on the Bacterial Lyase-re of Porcine Intestinal Heparin", 7	sistant Tetrasa	ccharides Derived from the	
De la constitución de la constit	C100	333-341, 1991.		•	Properties", J. Theor. Biol., 151:	
<u>网</u>	C101	YODER et al., "New Domain 1 Science, 260:1503-1506, 1993.		•		
B	C102	YODER et al., "Unusual Struct 1993.	ural Features in the Parallel β-h	elix in Pectate	Lyases", Structure, 1(4):241-251,	
P	C103	ZHANG et al., "6-O-Sulfotrans Biosynthetic Pathway", The Jo	sferase-1 Represents a Critical Eurnal of Biological Chemistry,			
	C104	ZHAO et al., "Rapid, Sensitive 1633, 1997.	Structure Analysis of Oligosac	charides", Proc	:. Natl. Acad. Sci. USA, 94: 1629-	
INE	P	_	DATE	ONGINERE	n .	

7

XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. clude copy of this form with next communication to applicant.

copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier ing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

OTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier plication, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier